Advertisement
Screener

OPKO Health, Inc. (OPK) Overview

OPKO Health, Inc. (OPK) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.01; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.07; Beat / miss (m).
  • 1 Oct 2025: Period ending 31 Dec 2025; Estimate (m); Actual -0.04; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.03; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$1.05$1.17$1.30$1.46$1.63$1.822025-11-062026-11-06$0.83$1.20$1.75$2.55$3.71$5.412021-11-082026-11-06$0.83$1.42$2.45$4.22$7.26$12.512016-11-072026-11-06$0.57$1.16$2.37$4.83$9.85$20.082006-11-062026-11-06$0.30$0.70$1.62$3.76$8.68$20.081995-11-022026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$1.72
Previous close
$1.62
Change
$0.10
Change (%)
6.17%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

OPK
+28.57%
S&P 500
(m)

1 year

OPK
+10.20%
S&P 500
(m)

3 years

OPK
+1.25%
S&P 500
(m)

5 years

OPK
-55.49%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.01

-0.27-0.15-0.030.090.2130 Jun 2025: estimate (m); actual -0.1930 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.0330 Sept 2025(m)31 Dec 2025: estimate (m); actual -0.0431 Dec 2025(m)31 Mar 2026: estimate (m); actual -0.0731 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.0130 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.01(m)(m)
1 Jan 202631 Mar 2026(m)-0.07(m)(m)
1 Oct 202531 Dec 2025(m)-0.04(m)(m)
1 Jul 202530 Sept 2025(m)0.03(m)(m)
1 Apr 202530 Jun 2025(m)-0.19(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.30

-0.54-0.37-0.21-0.040.1331 Dec 2021: estimate (m); actual -0.0531 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.4631 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.2531 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.0831 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.3031 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.30(m)(m)
1 Jan 202431 Dec 2024(m)-0.08(m)(m)
1 Jan 202331 Dec 2023(m)-0.25(m)(m)
1 Jan 202231 Dec 2022(m)-0.46(m)(m)
1 Jan 202131 Dec 2021(m)-0.05(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 163.58M ■ Earnings -8.42M — Profit margin -5.14%

-81.06M-45.2%9.22M-25.0%99.51M-4.9%189.79M15.3%30 Sept 2025: revenue 151.67M; earnings 21.63M; profit margin 14.26%30 Sept 202531 Dec 2025: revenue 148.45M; earnings -31.26M; profit margin -21.06%31 Dec 202531 Mar 2026: revenue 124.20M; earnings -54.85M; profit margin -44.16%31 Mar 202630 Jun 2026: revenue 163.58M; earnings -8.42M; profit margin -5.14%30 Jun 2026

31 Dec 2025 ■ Revenue 0.61B ■ Earnings -225.68B — Profit margin -37186.98%

-367.93B-37188.0%-231.78B-27279.4%-95.62B-17370.9%40.53B-7462.3%31 Dec 2022: revenue 1.00B; earnings -328.40B; profit margin -32703.28%31 Dec 202231 Dec 2023: revenue 0.86B; earnings -188.86B; profit margin -21871.93%31 Dec 202331 Dec 2024: revenue 0.71B; earnings -53.22B; profit margin -7463.31%31 Dec 202431 Dec 2025: revenue 0.61B; earnings -225.68B; profit margin -37186.98%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$1.72(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$1.72High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning OPK

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-13; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
2.91M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-6.36%*
Total return · month
9.46%*
Total return · quarter
7.28%*
Total return · half year
44.64%*
Total return · year to date
28.57%*
Total return · 1 year
10.20%*
Total return · 3 years
1.25%*
Total return · 5 years
-55.49%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

OPKO Health, Inc. Overview

View more →

(m)

(m)

SEC CIK
944809
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
4400 BISCAYNE BLVD., MIAMI, Florida, 33137, United States
Fiscal year end
1231
Phone
305-575-4181

Similar stocks

Stock NameCountryMarket CapPE Ratio
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
HARROW, INC. (HROW)United States$1.240B-42.77
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
Jaguar Health, Inc. (JAGX)United States$1.184B
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Avalyn Pharma Inc. (AVLN)United States$1.267B
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93